NCT05265728 - A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

January 18, 2024

Study Completion Date

May 27, 2024

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Natalizumab

Administered as specified in the treatment arm

Trial Locations (12)

Juntendo University Hospital, Bunkyō City

Chiba University Hospital, Chiba

St.Marianna University Hospital, Kawasaki-shi

National Center of Neurology and Psychiatry, Kodaira-shi

Kansai Medical University Medical Center, Moriguchi-shi

Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Ebara Hospital, Ōta-ku

The Kitasato Institute Kitasato University Hospital, Sagamihara-shi

National Hospital Organization Hokkaido Medical Center, Sapporo

Tohoku Medical and Pharmaceutical University Hospital, Sendai

Osaka University Hospital, Suita-shi

University of Tsukuba Hospital, Tsukuba

Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo-shi